A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Omilancor (Primary) ; Adalimumab
- Indications Crohn's disease
- Focus Pharmacodynamics
- Sponsors Landos Biopharma; NImmune Biopharma
- 10 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment. The closure of the study is driven by the decision to redesign the study protocol for future studies.
- 02 Nov 2021 Planned initiation date changed from 1 Sep 2021 to 1 Nov 2021.
- 23 Sep 2021 New trial record